# eversyn

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eversyn

- Industry: Biotechnology
- Headquarters: Magdeburg, Germany
- Website: www.eversyn.de/
- Total disclosed funding: $1.7M
- Latest round: Seed (Feb 17, 2025)
- Investors on record: 2

## About

Eversyn GmbH is focused on the development and commercialization of activated sugars and enzymes crucial for glycan engineering and protein glycosylation in the biopharmaceutical industry.Founded in 2022 in Magdeburg, Germany, eversyn GmbH specializes in glycan engineering and protein glycosylation through its advanced technology. The company has recently engaged in seed funding, raising EUR 1.6 million on March 20, 2025, led by BMP with participation from the Max Planck Foundation. Eversyn has completed 1 deal to date, which underlines its growth trajectory. The founder, whose name is not available, has a background in biotechnology and has previously worked in related fields.Eversyn specializes in the development and commercialization of activated sugars and enzymes, which serve as critical components for glycan engineering and protein glycosylation. Their core product offerings include affordable activated sugars, which are vital for creating human milk oligosaccharides (HMOs), specialty carbohydrates, and therapeutic proteins. These products are designed to overcome existing bottlenecks in research and development by making high-value glycans accessible to both academic researchers and industrial users. Eversyn's innovative technology allows for the precise manipulation of these molecules, thus unlocking new applications in the fields of nutrition and biopharmaceuticals. The company caters primarily to B2B clients within the European Economic Area (EEA) and has established partnerships intended to broaden its reach across various markets internationally.Eversyn operates on a B2B model, providing its products directly to research institutions and industrial partners focusing on glycoengineering applications. Transactions typically involve clients placing bulk orders for activated sugars and enzymes, with pricing structures in place that reflect the value and performance of these specialized products. For instance, activated sugars are priced starting at EUR 220 for up to 10 grams, while enzymes for in vitro glycoengineering begin at EUR 390 for up to 500 units. The company ensures a price guarantee on its offerings, reinforcing its commitment to affordability and accessibility in the market. Eversyn also engages in strategic partnerships and collaborations, further integrating its products into research and application-focused environments.In March 2025, eversyn GmbH raised EUR 1.6 million in seed funding to scale up its production capabilities, expand its team, accelerate ongoing research and development programs, and establish strategic partnerships. The company is focused on launching new products, including expanded offerings of activated sugars and enzymes targeted for the biopharmaceutical sector. Eversyn plans to enter new markets beyond the European Economic Area (EEA) by the end of 2026, highlighting its ambition to broaden its global footprint.

## Funding rounds

- Seed, Feb 17, 2025, $1.7M — BMP, Max Planck Foundation

## Investors

- BMP (https://capitalatlas.ai/funds/bmp) — Seed
- Max Planck Foundation — Seed